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doi:10.1016/j.jmii.2010.03.001Streptococcus pneumoniae, Haemophilus influenzae, and Staphylococcus aureus were respon-
sible for bacterial coinfection during previous or 2009 influenza pandemic and were associated
with a higher risk of influenza-related morbidity and mortality. Despite tuberculosis (TB) is still
a growing problem worldwide, Mycobacterial tuberculosis is rarely a copathogen with influenza.
We hereby report a cancer patient with TB and pandemic H1N1 influenza A virus coinfection.
Physicians should be aware that TB may present as a coinfection in an immunocompromised
patient with 2009 influenza A (H1N1) infection, especially in TB endemic area.
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Although the emergence and subsequent globally spread of
the 2009 pandemic influenza A (H1N1) has gained world-
wide concern, tuberculosis (TB) remains another serious
public health issue. According to the estimation of World
Health Organization, there were 13.7 million TB cases
globally with 9.27 million new cases and 1.76 million deathsished by Elsevier Taiwan LLC. All rights reserved.
Coinfection with Mycobacterium tuberculosis and pandemic influenza A (H1N1) virus 317from TB in 2007.1 In Taiwan, there were 14,265 newly
diagnosed TB cases with an incidence of 62 cases per
100,000 population and a TB mortality rate of 3.3 deaths
per 100,000 population in 2008.2 Moreover, the high prev-
alence of multidrug-resistant TB and the presence of
extensively drug-resistant TB in Taiwan is another poten-
tially devastating threat to TB control.3
During previous influenza pandemic, most deaths caused
by influenza A virus infection were accompanied by concur-
rent bacterial pneumonia.4,5 In 2009, study of autopsy
specimens from 77 fatal cases of confirmed pandemic influ-
enza A (H1N1) showed that 22 (29%) had concurrent bacterial
infection, and 10 of them were caused by Streptococcus
pneumoniae.6 However, the knowledge about coinfection
withMycobacterium tuberculosis (MTB) and pandemic H1N1
influenza virus is still limited.7 We hereby report a case with
TB and pandemic H1N1 Influenza A virus coinfection.
Case report
A 63-year-old man presented with fever and shortness of
breath on September 13, 2009. No headache, productive
cough, myalgia, vomiting, or diarrhea was complained. He
had a history of squamous cell lung cancer noted in 2007 and
was currently treated with chemotherapy and radiotherapy.
Dilated cardiomyopathy and coronary artery disease were
also diagnosed in 2009. The patient denied a history of travel
and animal contact, but he reported that his daughter was
diagnosed to have influenza A on September 14, 2009. His
body mass index was 26.8 kg/m2 and, vital signs were
temperature of 39C, pulse rate of 96/min, respiratory rate
of 26/min, and blood pressure of 116/74 mmHg. Physical
examinations were unremarkable except for bilateral coarse
crackle and diffuse wheezes on chest auscultation. The
results of laboratory tests were as below: white blood cell,
4,610 cell/mm3 (neutrophil, 82.4%; lymphocyte, 11.1%);
hematocrit, 31.1%; platelet count, 152,000 cell/mm3; serumFigure 1. (A) Chest radiography showing a mass lesion (lung canc
lesion (arrow head) over the left upper lobe, increased infiltration o
(B) chest computed tomography demonstrating a new developed co
middle lobe and right pleural effusion in a patient with lung cancer
influenza A (H1N1) virus.creatinine, 1.3 mg/dL; and C-reactive protein, 3.86 mg/dL
(normal < 0.8 mg/dL). Chest radiography and computed
tomography showed a mass lesion at the right paratracheal
region, a new developed consolidation lesion with air bron-
chogram over the right middle lobe, right pleural effusion,
and increased infiltration bilaterally (Fig. 1). No malignant
cells were found in the aspirated pleural effusion. Serolog-
ical tests for anti-Mycoplasma pneumoniae IgM (Savyon
Diagnostics Ltd., Ashdod, Israel), Binax NOW S pneumoniae
urinary antigen test (Binax Inc., Portland, ME, USA), and
Legionella urinary antigen test for serogroup 1 (Binax Inc.)
were all negative. The influenza rapid test (QuickVue Influ-
enza A þ B test; Biomerieux, San Diego, CA, USA) for
a nasopharyngeal swab sample was positive for influenza
A. An in-house real-time reverse transcriptase polymerase
chain reaction from nasopharyngeal swab sample was also
positive for 2009 pandemic influenza A (H1N1). He then
received a 5-day course of oseltamivir (75 mg twice daily).
The sputum culture yielded S pneumoniae, although the
quality of the sputum specimen was not acceptable (poly-
morphonuclear cells, 10e25 cells per low-power field and
epithelial cell count, 10e25 cells per low-power field).
Cefuroxime (250 mg every 12 hours) was also prescribed for
suspected coinfection of bacterial pneumonia. The patient
received antimicrobial treatment for 7 days and was dis-
charged uneventful. However, one sputum specimen coll-
ected during hospitalization was acid-fast smear negative
but grew MTB, which were susceptible to all anti-TB agents
tested. The patient then received anti-TB treatment
(isoniazid, rifampin, ethambutol, and pyrazinamide) since
October 9, 2009. Two sputum samples collected during
outpatient clinic visits also grew MTB.
Discussion
Previous studies showed that S pneumoniae, Haemophilus
influenzae, Staphylococcusaureus, and groupA Streptococcuser, arrow) at the right paratracheal region, a calcified nodular
ver the bilateral lung, and pleural effusion in the right lung and
nsolidation lesion with air bronchogram (arrow) over the right
who had coinfection with Mycobacterium tuberculosis and 2009
318 C.-K. Tan et al.were responsible for bacterial coinfection during previous or
2009 influenza pandemic,4e6 but active TB coinfection was
only reported in seven fatal pandemic H1N1 influenza infec-
tion cases in South Africa.7 This is the first case with labora-
tory-confirmed coinfection with pandemic H1N1 influenza
virus andMTB inan immununocompromisedpatient in Taiwan,
an area with a high incidence of TB. Although sputum culture
was positive for S pneumoniae in this patient, the poor quality
of the sputum specimen and negative urinary pneumococcal
antigen testing excluded the possibility of coinfection with
S pneumonaie.
It should be noted that persons with risk factors for
severe complications from pandemic 2009 influenza A
infection, such as chronic lung disease and immunosup-
pression,8 also appear to be at risk of TB. In the present
report, the immunocompromised status from his lung
cancer would have contributed both to the development
of TB and to the onset of influenza. Furthermore, early
diagnosis of TB is crucial for patients that receiving
immunosuppressive treatments, such as cancer chemo-
therapy and immunomodulatory agents, because delay in
diagnosis may contribute to morbidity and mortality.
Therefore, MTB should also be considered as one of the
important copathogens with pandemic H1N1 influenza A
infection to avoid delay diagnosis in the area with a high
prevalence of TB.
Previous studies showed that bacterial coinfection was
associated with a higher risk of influenza-related morbidity
and mortality.4e6 Likewise, active TB coinfection might also
be associated with a higher morbidity and mortality in
patients with influenza. TB was associated in 10% of the
2009 influenza A (H1N1) fatality cases in South Africa, and
even higher (19%) in deceased pregnant women.7 It is
difficult to determine a cause and effect relationship
between TB coinfection and mortality based on the rare
occurrences of TB coinfection with influenza A, furtherepidemiology study is need to clarify the role of TB coin-
fection in contribution to severe complications.
In conclusion, physicians should be aware that TB may
present as a coinfection in an immunocompromised patient
with 2009 influenza A (H1N1) infection, especially in TB
endemic area.
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